Antibody Information

General Information of This Antibody

Antibody ID	ANI0OAWPH
Antibody Name	Anti-MUC1 mAb hCTM01
Organization	Celltech, UCB
Indication	Ovarian cancer; Breast cancer
Synonyms	7F11C7; CTM01-humanized; hCTM01 Click to Show/Hide
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG4-kappa
Antigen Name	Mucin-1 (MUC1)	Antigen Info
PDB ID	1ad9
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Varible Domain	EIQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYINWMRQAPGQGLEWIGWIDPGSGNTKY NEKFKGRATLTVDTSTNTAYMELSSLRSEDTAFYFCAREKTTYYYAMDYWGQGTLVTVSS Click to Show/Hide
Heavy Chain Constant Domain 1	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVE Click to Show/Hide
Heavy Chain CDR 1	GYTFTDYY Click to Show/Hide
Heavy Chain CDR 2	IDPGSGNT Click to Show/Hide
Heavy Chain CDR 3	AREKTTYYYAMDY Click to Show/Hide
Light Chain Varible Domain	DIQMTQSPSTLSASVGDRVTITCRSSKSLLHSNGDTFLYWFQQKPGKAPKLLMYRMSNLA SGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCMQHLEYPFTFGQGTKVEVK Click to Show/Hide
Light Chain Constant Domain	RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
Light Chain CDR 1	KSLLHSNGDTF Click to Show/Hide
Light Chain CDR 2	RMS Click to Show/Hide
Light Chain CDR 3	MQHLEYPFT Click to Show/Hide

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

CMB-401 [Terminated in phase 2]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Objective Response Rate (ORR)	0.00%
Patients Enrolled	Platinum-sensitive EOC (recurrence >6 months after completion of an initial platinumcontaining chemotherapy regimen).
Administration Dosage	Initial infusion of 35 mg/m² of hCTM01 (anti-PEM antibody not conjugated to calicheamicin) over a period of 15 min, followed 45 min later (60 min from the start of the initial infusion) by an infusion of 16 mg/m² of CMB-401 over an additional 60 min, up to 7 cycles, with 4 weeks between cycles.
Experiment 2 Reporting the Activity Date of This ADC			[2]
Patients Enrolled	EOC refractory to or unsuitable for platinum/standard therapy; with a WHO performance status of 0-2; life expectancy of more than three months and fulfilling other standard eligibility criteria.
Administration Dosage	Up to four cycles of a dual infusion of 35.00 mg/m² hCTMO1 'predose' followed by doses of CMB-401 which were increased for each cohort, CMB-401 dosing commenced at 2 mg/m² and progressed via seven cohorts to 16.00 mg/m².

References

Ref 1	A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother. 2003 Apr;52(4):243-8.
Ref 2	Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol. 2000 Jun;11(6):735-41.